PIK3C2A and head and neck squamous cell carcinoma: They identified PIK3C2A as the only gene that depleted both gefitinib and erlotinib levels, and transient knockdown of this gene using an siRNA approach sensitized HNSCC cells to gefitinib treatment in vitro.